Table 1.
Baseline characteristics of the two groups before treatment.
| YXTZTs (n = 34) | Placebo (n = 34) | X2 or t or Z | P | |
|---|---|---|---|---|
| Male/female | 20/14 | 26/8 | 2.419 | 0.120 |
| Age | 61.76 ± 5.33 | 62.69 ± 4.32 | 0.450 | 0.654 |
| Education (M/H/C) | 3/28/3 | 4/29/1 | 3.212 | 0.201 |
| Baseline of ADAS-COG | 12.74 ± 2.48 | 12.76 ± 2.71 | 0.540 | 0.589 |
| Baseline of CIBIC-PLUS | 13.09 ± 2.56 | 13.15 ± 1.65 | 1.778 | 0.075 |
| Baseline of MMSE | 24.00 (23.00, 25.00) | 24.00 (24.00, 25.00) | −0.409 | 0.682 |
| Baseline of IL-6 | 4.81 (2.54, 14.60) | 6.00 (4.09, 12.00) | −0.933 | 0.351 |
| Baseline of IL-8 | 25.70 (11.28, 39.13) | 18.00 (12.23, 35.20) | −0.276 | 0.783 |
| Baseline of TNF-α | 12.70 (8.28, 17.98) | 14.00 (12.00, 15.23) | −1.086 | 1.277 |
Note. YXTZTs: Yin-Xing-Tong-Zhi tablets; M: middle school; H: high school; C: college; ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive subscale; CIBIC-Plus: Clinician Interview based Impression of Severity; MMSE: Mini–Mental State Examination; IL-6: interleukin-6; IL-8: interleukin-8; TNF-α: tumor necrosis factor.